Search clinical trials for: Placebo matching with BMS-986020

Total 2522 results

Bristol-Myers Squibb

Completed

A Study of Experimental Medication BMS-986235 in Healthy Subjects

Mediators of Inflammation

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986166 in Healthy Japanese Participants

Healthy Volunteers

United States
Bristol-Myers Squibb

Completed

A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis C

Liver Fibrosis | Hepatic Cirrhosis

United States
Bristol-Myers Squibb

Completed

A Study of Experimental Medication BMS-986278 Given to Healthy Participants

Healthy Participants

United Kingdom, Netherlands
Bristol-Myers Squibb

Completed

A Study of BMS-582949 in Patients With Moderate to Severe Plaque Psoriasis

Psoriasis

Australia, Canada, Mexico
Bristol-Myers Squibb

Completed

A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986104 in Healthy Male Subjects

Rheumatoid Arthritis

United States
Bristol-Myers Squibb

Withdrawn

Japanese Bridging Study Conducted in the United States

Hepatitis C Virus

United States
Bristol-Myers Squibb

Completed

Safety Study of BMS-816336 in Healthy Male Subjects

Dyslipidemia | Diabetes Mellitus, Non-Insulin-Dependent

Australia
Bristol-Myers Squibb

Completed

Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-708163

Alzheimer's Disease

United States
Bristol-Myers Squibb

Completed

Safety Study of Multiple-dose of Gamma-secretase Inhibitor in Healthy Male Japanese and Healthy Elderly Japanese (JMAD)

Healthy

Japan
Bristol-Myers Squibb

Completed

A Study of BMS-562086 in Patients With Irritable Bowel Syndrome

Irritable Bowel Syndrome

United States
Bristol-Myers Squibb
Nektar Therapeutics

Completed

A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer

Bladder Cancer | Bladder Tumor | Muscle-Invasive Bladder Cancer

Russian Federation, China, Germany, Italy, United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Czechia, France, Greece, Israel, Mexico, Netherlands, Poland, Spain, United Kingdom
Universidade Ibirapuera

Withdrawn

Pre-etching of Dentin Before Restorations With High Viscosity Glass Ionomer Cement (CEPECO4)

Dental Caries

Brazil
Cognition Therapeutics
National Institute on Aging (NIA); Alzheimer's Clinical Trials Consortium

Recruiting

A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease

Early Alzheimer's Disease

United States
Bristol-Myers Squibb

Completed

Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery (ADVANCE-2)

Deep Vein Thrombosis | Pulmonary Embolism

Italy, Korea, Republic of, China, Spain, South Africa, Colombia, Austria, France, Germany, Israel, Russian Federation, Denmark, Belgium, Singapore, Brazil, Mexico, Norway, Philippines, Poland, Ukraine, India, Malaysia, Hungary, Chile, Czech... and more
M.D. Anderson Cancer Center

Recruiting

Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases

Melanoma (Skin)

United States
Bristol-Myers Squibb

Completed

A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced Tumors

Advanced Cancer

Japan
Biogen
Denali Therapeutics Inc.

Recruiting

A Study to Assess the Safety of BIIB122 Tablets and if it Can Slow the Worsening of Early-Stage Parkinson's Disease in Participants Between the Ages of 30 and 80 (LUMA)

Parkinson Disease

United States, Netherlands, Italy, Spain, Israel, Canada, China, Germany, France, Austria, United Kingdom, Poland, Japan
AbbVie

Recruiting

Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

Migraine

United States, Puerto Rico
Celldex Therapeutics

Active, not recruiting

A Study of CDX-0159 in Patients With Chronic Inducible Urticaria

Chronic Inducible Urticaria

United States, Latvia, Spain, Poland, Georgia, South Africa, Germany, Lithuania, Estonia, Hungary, Bulgaria
Celldex Therapeutics

Active, not recruiting

A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria

Chronic Spontaneous Urticaria

Spain, United States, Poland, Georgia, South Africa, Bulgaria, Hungary, Estonia, Germany
Biogen
Denali Therapeutics Inc.

Terminated

A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (LIGHTHOUSE)

Parkinson Disease

United States, Italy, Spain, Germany, France, United Kingdom
Idorsia Pharmaceuticals Ltd.

Completed

Single Oral Dose of 4 mg Cenerimod in Healthy Japanese and Caucasian Subjects

Healthy Volunteers

United States
Alzheon Inc.
Quotient Clinical

Completed

Multiple Ascending Dose Study of ALZ-801

Alzheimer Disease

United Kingdom
GlaxoSmithKline

Completed

To Investigate If Single Doses Of GSK618334 Are Safe And To Investigate Blood Levels Of GSK618334

Substance Dependence

United Kingdom
Beech Tree Labs, Inc.
Norwich Clinical Research Associates Ltd.; Hill Top Research

Completed

Evaluation of Cold Sore Treatments on Ultra Violet (UV) Induced Cold Sores

Oral Herpes Simplex

United States
Beech Tree Labs, Inc.
Norwich Clinical Research Associates Ltd.

Completed

Safety and Efficacy Study of a New Treatment for Recurrent Symptoms of Oral Herpes Virus Infection

Oral Herpes Simplex

United States
Novartis Pharmaceuticals

Recruiting

A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis

Aortic Stenosis

Switzerland, Canada, Israel, United States, United Kingdom
Boehringer Ingelheim

Completed

Single Rising Dose Study of BI 207127 NA in Healthy Male Asian Volunteers and Single Dose Study of BI 207127 NA in Healthy Male Caucasian Volunteers

Healthy

Korea, Republic of
Incyte Corporation

Terminated

A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)

Solid Tumors

United States
AstraZeneca

Completed

Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

Diabetes Mellitus, Type 2

United States, Canada, Mexico, Puerto Rico, Taiwan, Australia
Midnight Pharma, LLC

Completed

Almorexant (ACT-078573) in Elderly Subjects With Chronic Primary Insomnia

Chronic Primary Insomnia

United States
Gmax Biopharm Australia Pty Ltd.

Completed

Assessment of the Safety, Tolerability, and Pharmacokinetic of GMA106

Overweight and Obesity

Australia
Syneos Health

Recruiting

First-in-Human Study of VB0004 in Healthy Subjects and to Patients With Mild to Moderate Hypertension With Low Cardiovascular Risk

Hypertension

Australia
Karyopharm Therapeutics Inc
GOG Foundation; Israeli Society of Gynecologic Oncology; Belgium and Luxembourg... and other collaborators

Active, not recruiting

Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO] (ENGOT-EN5)

Endometrial Cancer

United States, China, Israel, Spain, Belgium, Germany, Greece, Czechia, Italy, Canada
Institut de Recherches Internationales Servier

Active, not recruiting

Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)

Recurrent Glioma | Grade 2 Glioma | Residual Glioma

United States, Canada, Spain, Italy, United Kingdom, Switzerland, Israel, Japan, Netherlands, Germany, France
Novartis Pharmaceuticals

Completed

Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease

Cushings Disease

United States, Canada, Italy, India, Japan, Austria, Netherlands, Spain, Korea, Republic of, Germany, Thailand, France, Bulgaria, Turkey, Colombia, China, Argentina, Russian Federation, United Kingdom
Nathura S.p.A
Evidilya S.r.l.

Completed

A New Class IIb MD in Proctological Disorders

Proctological Disorders

Italy
Regeneron Pharmaceuticals

Completed

Study to Assess the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of a Single Dose of REGN5713-5714-5715 in Healthy Adult Participants

Healthy Volunteers | Birch Pollen Allergy

Belgium
Kubota Vision Inc.
Otsuka Pharmaceutical Co., Ltd.

Completed

Safety and Tolerability of Repeat Doses of ACU-4429 in Healthy Subjects

Healthy

United States
Takeda

Completed

Single-Dose Study of MT203

Healthy Volunteers

Japan
Bristol-Myers Squibb

Recruiting

A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986454 in Healthy Participants

Healthy Participants

United Kingdom
Bristol-Myers Squibb

Withdrawn

A Single and Multiple Ascending Dose Study of BMS-986318 in Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Completed

Safety and Tolerability Study of BMS-986177 in Healthy Subjects

Thrombosis

Belgium
Bristol-Myers Squibb

Completed

Crossover Post-herpetic Neuralgia (PHN)

Post-Herpetic Neuralgia (PHN)

United States, France
Bristol-Myers Squibb

Completed

Safety, Pharmacokinetics and Pharmacodynamics Study to Evaluate BMS-830216 in Obese Subjects

Obesity

United States
Bristol-Myers Squibb

Completed

BMS-741672 for Diabetic Neuropathic Pain

Neuropathic Pain

United States
Bristol-Myers Squibb

Completed

A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

Sweden, United States, Denmark, Finland
Bristol-Myers Squibb

Completed

Randomized, Placebo-Controlled, Double-Blind, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-963272 in Healthy Subjects

Healthy

United States
Bristol-Myers Squibb
Solvay Pharmaceuticals

Terminated

Multiple-dose Study to Evaluate the Efficacy, Safety and Pharmacokinetics of BMS-646256 in Obese Subjects

Obesity

United States

Search clinical trials for: Placebo matching with BMS-986020

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Luxembourg

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations